Cargando…

Combining HDAC and MEK Inhibitors with Radiation against Glioblastoma-Derived Spheres

Glioblastoma stem-like cells (GSLCs) in glioblastoma limit effective treatment and promote therapeutic resistance and tumor recurrence. Using a combined radiation and drug-screening platform, we tested the combination of a histone deacetylase inhibitor (HDACi) and MAPK/ERK kinase inhibitor (MEKi) wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Essien, Eno I., Hofer, Thomas P., Atkinson, Michael J., Anastasov, Nataša
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909581/ https://www.ncbi.nlm.nih.gov/pubmed/35269397 http://dx.doi.org/10.3390/cells11050775

Ejemplares similares

Comparison of Radiosensitization by HDAC Inhibitors CUDC-101 and SAHA in Pancreatic Cancer Cells
por: Moertl, Simone, et al.
Publicado: (2019)

MEK1 Inhibitor Combined with Irradiation Reduces Migration of Breast Cancer Cells Including miR-221 and ZEB1 EMT Marker Expression
por: Anastasov, Nataša, et al.
Publicado: (2020)

Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma
por: Schreck, Karisa C, et al.
Publicado: (2020)

HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma
por: Sriramareddy, Sathya Neelature, et al.
Publicado: (2022)

A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells
por: Ischenko, Irene, et al.
Publicado: (2015)

HDAC inhibitors and their potential applications to glioblastoma therapy
por: Adamopoulou, Eleni, et al.
Publicado: (2013)

Inhibition of glioblastoma dispersal by the MEK inhibitor PD0325901
por: Shannon, Stephen, et al.
Publicado: (2017)

Metabolic Effects of Known and Novel HDAC and SIRT Inhibitors in Glioblastomas Independently or Combined with Temozolomide
por: Cuperlovic-Culf, Miroslava, et al.
Publicado: (2014)

Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
por: Chao, Min-Wu, et al.
Publicado: (2019)

Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma
por: Auzmendi-Iriarte, Jaione, et al.
Publicado: (2020)

BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma
por: Gusyatiner, Olga, et al.
Publicado: (2021)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

The limitations of targeting MEK signalling in Glioblastoma therapy
por: Selvasaravanan, Karthika D., et al.
Publicado: (2020)

Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines
por: Sixto-López, Yudibeth, et al.
Publicado: (2020)

Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma
por: Ryu, Sunhyo, et al.
Publicado: (2017)

The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells
por: Berghauser Pont, Lotte M.E., et al.
Publicado: (2015)

Assessing Treatment Response of Glioblastoma to an HDAC Inhibitor Using Whole-Brain Spectroscopic MRI
por: Gurbani, Saumya S., et al.
Publicado: (2019)

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
por: Atefi, Mohammad, et al.
Publicado: (2015)

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
por: Booth, Andrew E. C., et al.
Publicado: (2020)

Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy
por: Nakashima, Hiroshi, et al.
Publicado: (2015)

Radiation resistance due to high expression of miR-21 and G2/M checkpoint arrest in breast cancer cells
por: Anastasov, Nataša, et al.
Publicado: (2012)

Phenylbutyrate—a pan-HDAC inhibitor—suppresses proliferation of glioblastoma LN-229 cell line
por: Kusaczuk, Magdalena, et al.
Publicado: (2015)

Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor
por: Dumble, Melissa, et al.
Publicado: (2014)

HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases
por: Yoon, Somy, et al.
Publicado: (2016)

MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy
por: Tran, Khiem A, et al.
Publicado: (2015)

Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors
por: Stewart, A., et al.
Publicado: (2015)

Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation
por: Meirson, Tomer, et al.
Publicado: (2020)

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
por: Heinzerling, Lucie, et al.
Publicado: (2019)

Gossypol Suppresses Growth of Temozolomide-Resistant Glioblastoma Tumor Spheres
por: Kim, Hee Yeon, et al.
Publicado: (2019)

Discovery of New Uracil and Thiouracil Derivatives as Potential HDAC Inhibitors
por: Elbatrawy, Omnia R., et al.
Publicado: (2023)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023)

Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy
por: Everix, Liesbeth, et al.
Publicado: (2023)

A 3D-microtissue-based phenotypic screening of radiation resistant tumor cells with synchronized chemotherapeutic treatment
por: Anastasov, Nataša, et al.
Publicado: (2015)

Dual blockade of PI3K and MEK in combination with radiation in head and neck cancer
por: Blas, Kevin, et al.
Publicado: (2018)

Recent Update of HDAC Inhibitors in Lymphoma
por: Chen, I-Chung, et al.
Publicado: (2020)

IDH1(R132H) Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells
por: Kim, Geon-Hee, et al.
Publicado: (2019)

Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective
por: King, Jacob, et al.
Publicado: (2021)

Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model
por: Lai, Xiulan, et al.
Publicado: (2017)

MEK inhibitors against MET-amplified non-small cell lung cancer
por: Chiba, Masato, et al.
Publicado: (2016)

Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma
por: Hui, Caressa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_98d8cihkle393s3gve4065oqhk